Background: Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in ...

Sodium–glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease–mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1–3 chronic kidney disease ...

To search for a full-text article published before 1997, see PubMed Central. To view themed issues and supplements, see Supplements.

Background: Whether people experiencing homelessness (PEH) have different COVID-19 outcomes than housed patients in Canada remains unclear. We sought to ascertain whether rates of in-hospital ...

Medicine and society: Nonceliac gluten sensitivities: encouraging patients through epistemic humility ...

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca ...

Correction to “Nomenclature revision may mitigate potential overtreatment of incidental finding of coronary calcium on chest computed tomography” ...

Five Things to Know About ...: Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes ...

Sodium–glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease–mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1–3 chronic kidney disease ...